BeyondSpring Inc. (NASDAQ: BYSI) announced results from an Asian subset analysis of its Phase 3 DUBLIN-3 trial evaluating plinabulin plus ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE